Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine to Prevent Falls in Parkinson's Disease
NCT04226248Phase 3Completed
- Sponsor
- University of Bristol
- Start
- Jan 2020
- Primary completion
- May 2024
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of rivastigmine in Parkinson's disease (PD), sponsored by University of Bristol. Started Jan 2020; status: completed.
02
Drugs
rivastigmine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04226248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04226248.